Your session is about to expire
What is Arixtra
FondaparinuxThe Generic name of this drug
Treatment SummaryFondaparinux (Arixtra) is a man-made anticoagulant that helps prevent the formation of blood clots. It is similar to heparin and heparan sulfate, which contain small molecules that bind to antithrombin III, an enzyme that helps stop blood clots from forming. Fondaparinux binds even more tightly to antithrombin III and is 300 times more effective in stopping blood clots from forming. It is used to prevent blood clots after orthopedic surgery, abdominal surgery, and for the treatment of deep vein thrombosis, pulmonary emb
Arixtrais the brand name
Arixtra Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Arixtra
Fondaparinux
2001
46
Effectiveness
How Arixtra Affects PatientsFondaparinux works by increasing the activity of the body's natural anticoagulant (ATIII) which helps to stop the formation of blood clots. It has no known effect on platelet function, and it does not affect fibrinolytic activity or bleeding time. Generally, monitoring of fondaparinux is not needed, but it may be recommended for those with kidney problems or pregnant women. It is important to keep track of kidney function and complete blood count (CBC) during treatment. There is currently no antidote for fondaparinux.
How Arixtra works in the bodyFondaparinux is an anticoagulant drug that stops the formation of blood clots by preventing Factor Xa from working. Factor Xa is an important part of the blood clotting process, so by blocking it, fondaparinux interrupts the clotting process and prevents thrombus formation. Fondaparinux does not usually cause the same side effects as other anticoagulants, such as heparin-induced thrombocytopenia, but rare cases have been reported.
When to interrupt dosage
The endorsed measure of Arixtra is contingent upon the identified condition, including Unstable Angina Pectoris, Deep Vein Thrombosis and Deep Vein Thrombosis. The measure of dosage fluctuates, as per the procedure of delivery (e.g. Solution - Intravenous; Subcutaneous or Subcutaneous) outlined in the subsequent table.Condition
Dosage
Administration
Abdominal Surgeries
, 50.0 mg/mL, 25.0 mg/mL, 75.0 mg/mL, 100.0 mg/mL, 15.0 mg/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Subcutaneous
Pulmonary Embolism
, 50.0 mg/mL, 25.0 mg/mL, 75.0 mg/mL, 100.0 mg/mL, 15.0 mg/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Subcutaneous
Myocardial Infarction
, 50.0 mg/mL, 25.0 mg/mL, 75.0 mg/mL, 100.0 mg/mL, 15.0 mg/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Subcutaneous
Total Knee Arthroplasty
, 50.0 mg/mL, 25.0 mg/mL, 75.0 mg/mL, 100.0 mg/mL, 15.0 mg/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Subcutaneous
acute, superficial, symptomatic Vein Thrombosis
, 50.0 mg/mL, 25.0 mg/mL, 75.0 mg/mL, 100.0 mg/mL, 15.0 mg/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Subcutaneous
Deep Vein Thrombosis
, 50.0 mg/mL, 25.0 mg/mL, 75.0 mg/mL, 100.0 mg/mL, 15.0 mg/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Subcutaneous
Heart Attack
, 50.0 mg/mL, 25.0 mg/mL, 75.0 mg/mL, 100.0 mg/mL, 15.0 mg/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Subcutaneous
Fracture
, 50.0 mg/mL, 25.0 mg/mL, 75.0 mg/mL, 100.0 mg/mL, 15.0 mg/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Subcutaneous
Hip structure
, 50.0 mg/mL, 25.0 mg/mL, 75.0 mg/mL, 100.0 mg/mL, 15.0 mg/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Subcutaneous
Unstable Angina Pectoris
, 50.0 mg/mL, 25.0 mg/mL, 75.0 mg/mL, 100.0 mg/mL, 15.0 mg/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Subcutaneous
Warnings
Arixtra ContraindicationsCondition
Risk Level
Notes
body weight <50 kg
Do Not Combine
Bacterial Endocarditis
Do Not Combine
Low Platelet Count
Do Not Combine
Hemorrhage
Do Not Combine
Common Arixtra Drug Interactions
Drug Name
Risk Level
Description
Albutrepenonacog alfa
Major
The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Fondaparinux.
Andexanet alfa
Major
The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Fondaparinux.
Anti-inhibitor coagulant complex
Major
The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Fondaparinux.
Antihemophilic factor (recombinant), PEGylated
Major
The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Fondaparinux.
Antihemophilic factor human
Major
The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Fondaparinux.
Arixtra Toxicity & Overdose RiskTaking anticoagulants can increase the risk of bleeding. This risk may be amplified in those with kidney or liver issues, or in people who weigh less than 50kg.
Arixtra Novel Uses: Which Conditions Have a Clinical Trial Featuring Arixtra?
54 active trials are currently being conducted to assess the potential of Arixtra to treat Total Knee Replacement, Unstable Angina Pectoris and Deep Vein Thrombosis.Condition
Clinical Trials
Trial Phases
Deep Vein Thrombosis
17 Actively Recruiting
Phase 4, Phase 3, Not Applicable, Phase 1, Phase 2
Unstable Angina Pectoris
0 Actively Recruiting
Fracture
1 Actively Recruiting
Not Applicable
Hip structure
1 Actively Recruiting
Not Applicable
Myocardial Infarction
4 Actively Recruiting
Phase 3, Not Applicable, Phase 4
Total Knee Arthroplasty
15 Actively Recruiting
Phase 3, Not Applicable, Phase 2, Phase 4
Pulmonary Embolism
4 Actively Recruiting
Not Applicable, Phase 2
Abdominal Surgeries
3 Actively Recruiting
Phase 3, Not Applicable
acute, superficial, symptomatic Vein Thrombosis
0 Actively Recruiting
Heart Attack
8 Actively Recruiting
Not Applicable, Phase 2, Phase 3
Arixtra Reviews: What are patients saying about Arixtra?
5Patient Review
6/26/2011 I was diagnosed with portal vein thrombosis in 2002 and placed on coumadin. During the next two years, I had reoccurring lung clots in my upper and lower lobes. Lovenox and Arixtra have been a miracle drug for me; I haven't had any clots in four years. This will be a life-time drug for me also. My condition today is fair with much fatigue. I also have Budd-Chiari syndrome, which Arixtra is helping with the inflow and outflow of liver blood. I am blessed to be given a longer life with my family--
5Patient Review
7/13/2011 I really appreciate how easy it is to use this self-dosing needle. They retract into the cartridge so you don't have to worry about disposing of them, and if you follow the directions they cause very little pain. I also haven't had any side effects, which is amazing because I'm sensitive to a lot of medications. And it's great that my health insurance covers such a large percentage of the cost!
5Patient Review
9/18/2015 I couldn't tolerate the other options, but this one really works well for me. The only downside is that you have to pinch your skin while administering the shot, but it's worth it to avoid bruising.
5Patient Review
2/20/2019 Coumadin and other therapies failed me, so I had to switch to Arixtra. It's been eight years with no side effects. This medication is expensive, but it saved my life.
4.7Patient Review
1/19/2011 I have antiphosolipid antibody syndrome and have been on warfarin for 3yrs. A recent misdiagnosis of a blood clot has now left me with no choice but heparin for life. I have found the cost of arixtra to be exhorbitant compared to warfarin and the bruising and hematomas are awful, though not as bad as lovenox.
4.3Patient Review
9/12/2010 I have been on Arixtra injections for 10 months, as per my doctor's recommendation, and I am wondering about the long-term effects of this medication. From what I can tell, there are a range of potential side effects associated with its use. Has anyone else experienced any problems?
4.3Patient Review
8/17/20103.7Patient Review
1/21/2013 I would prefer an pill or something over having to take a daily shot, but this treatment is still helpful. I'm only 19 and will have to take it for the rest of my life though, so hopefully they come out with an easier way to administer it soon.
2.3Patient Review
4/14/2012 This is extremely difficult to administer, even for professionals. The consumer information is very lacking, and it's so new that pharmacists and doctors are not familiar with it. I can't find any long term clinical studies on this either.
1.7Patient Review
10/4/2012 This treatment caused me to develop a rash on my upper arms and chest, as well as bruising and bleeding from my wound. Overall, I was not pleased with the results.
Patient Q&A Section about arixtra
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What type of drug is Arixtra?
"Arixtra belongs to a class of drugs called factor Xa (ten A) inhibitors, which work by reducing the ability of blood to clot."
Answered by AI
What is the drug Arixtra used for?
"Fondaparinux is a medication that is used to treat serious blood clots. It is usually used in conjunction with another medication called warfarin. If blood clots are not treated, they can travel to the lungs, heart, or brain and cause serious problems such as a heart attack or stroke."
Answered by AI
Is Arixtra the same as Lovenox?
"Arixtra is used to prevent and treat DVT and pulmonary embolism (blood clots in the lungs).
Are Arixtra and Lovenox the same thing? No, they are not. Lovenox is a blood thinner (anticoagulant) used to prevent blood clots. Arixtra is also a blood thinner used to prevent and treat DVT and pulmonary embolism (blood clots in the lungs)."
Answered by AI
Is Arixtra a heparin product?
"Arixtra (fondaparinux) is not a type of heparin. It is an anticoagulant that prevents and treats blood clots, but it works in a different way. It can be a good option for people who are allergic to heparin products."
Answered by AI